Listed

MoonLake Immunotherapeutics

MLTXNasdaqCIK 1821586HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$61.7m, Q2 FY2026
Net income−$61.8m, Q2 FY2026
MoonLake Immunotherapeutics, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m7.6Research and development, Q3 FY2023, three months to 2023-09-30$7.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure8.1Research and development, Q4 FY2023, three months to 2023-12-31$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure13.0Research and development, Q1 FY2024, three months to 2024-03-31$13.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure23.7Research and development, Q2 FY2024, three months to 2024-06-30$23.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure35.7Research and development, Q3 FY2024, three months to 2024-09-30$35.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure40.4Research and development, Q4 FY2024, three months to 2024-12-31$40.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure36.5Research and development, Q1 FY2025, three months to 2025-03-31$36.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure49.8Research and development, Q2 FY2025, three months to 2025-06-30$49.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure60.6Research and development, Q3 FY2025, three months to 2025-09-30$60.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure56.0Research and development, Q4 FY2025, three months to 2025-12-31$56.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure54.5Research and development, Q1 FY2026, three months to 2026-03-31$54.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure50.2Research and development, Q2 FY2026, three months to 2026-06-30$50.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Operating income$m(13.0)Operating income, Q3 FY2023, three months to 2023-09-30−$13.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure(15.0)Operating income, Q4 FY2023, three months to 2023-12-31−$15.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(19.8)Operating income, Q1 FY2024, three months to 2024-03-31−$19.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure(30.6)Operating income, Q2 FY2024, three months to 2024-06-30−$30.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure(43.1)Operating income, Q3 FY2024, three months to 2024-09-30−$43.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure(49.6)Operating income, Q4 FY2024, three months to 2024-12-31−$49.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(47.5)Operating income, Q1 FY2025, three months to 2025-03-31−$47.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(60.7)Operating income, Q2 FY2025, three months to 2025-06-30−$60.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure(71.4)Operating income, Q3 FY2025, three months to 2025-09-30−$71.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure(65.2)Operating income, Q4 FY2025, three months to 2025-12-31−$65.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(70.0)Operating income, Q1 FY2026, three months to 2026-03-31−$70.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(61.7)Operating income, Q2 FY2026, three months to 2026-06-30−$61.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Interest expense$mnot reportednot reported0.0Interest expense, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure0.0Interest expense, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$18.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure2.0Interest expense, Q2 FY2025, three months to 2025-06-30$2.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure3.2Interest expense, Q3 FY2025, three months to 2025-09-30$3.2m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure2.0Interest expense, Q4 FY2025, three months to 2025-12-31$2.0m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure2.3Interest expense, Q1 FY2026, three months to 2026-03-31$2.3m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure2.6Interest expense, Q2 FY2026, three months to 2026-06-30$2.6m. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$28.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$43.9k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2024, three months to 2024-03-31$70.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure0.1Income tax, Q2 FY2024, three months to 2024-06-30$79.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure0.1Income tax, Q3 FY2024, three months to 2024-09-30$92.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$41.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.2Income tax, Q1 FY2025, three months to 2025-03-31$153.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure0.1Income tax, Q2 FY2025, three months to 2025-06-30$95.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure0.1Income tax, Q3 FY2025, three months to 2025-09-30$115.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure0.2Income tax, Q4 FY2025, three months to 2025-12-31$248.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.6Income tax, Q1 FY2026, three months to 2026-03-31$622.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure0.1Income tax, Q2 FY2026, three months to 2026-06-30$90.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Net income$m(9.4)Net income, Q3 FY2023, three months to 2023-09-30−$9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure(7.4)Net income, Q4 FY2023, three months to 2023-12-31−$7.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(13.7)Net income, Q1 FY2024, three months to 2024-03-31−$13.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure(24.3)Net income, Q2 FY2024, three months to 2024-06-30−$24.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure(35.4)Net income, Q3 FY2024, three months to 2024-09-30−$35.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure(45.6)Net income, Q4 FY2024, three months to 2024-12-31−$45.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(39.9)Net income, Q1 FY2025, three months to 2025-03-31−$39.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(55.2)Net income, Q2 FY2025, three months to 2025-06-30−$55.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure(69.7)Net income, Q3 FY2025, three months to 2025-09-30−$69.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure(62.4)Net income, Q4 FY2025, three months to 2025-12-31−$62.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(69.7)Net income, Q1 FY2026, three months to 2026-03-31−$69.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(61.8)Net income, Q2 FY2026, three months to 2026-06-30−$61.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Diluted EPS$ per share(0.18)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figurenot reported(0.22)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure(0.39)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure(0.56)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figurenot reported(0.63)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(0.87)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure(1.10)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figurenot reported(0.98)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(0.84)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Basic EPS$ per share(0.18)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figurenot reported(0.22)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.22 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure(0.39)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure(0.56)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figurenot reported(0.63)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(0.87)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure(1.10)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figurenot reported(0.98)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(0.84)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.84 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure

Balance sheet

Cash and equivalents$477.9m, Q2 FY2026
Long-term debt$99.5m, Q2 FY2026
Shareholders' equity$428.2m, Q2 FY2026
MoonLake Immunotherapeutics, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m318Cash and equivalents, Q3 FY2023, at 2023-09-30$318.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure451Cash and equivalents, FY2023, at 2023-12-31$451.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-26, accession 0001821586-25-000006.Report this figure458Cash and equivalents, Q1 FY2024, at 2024-03-31$458.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure343Cash and equivalents, Q2 FY2024, at 2024-06-30$342.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure376Cash and equivalents, Q3 FY2024, at 2024-09-30$375.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure180Cash and equivalents, FY2024, at 2024-12-31$180.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure272Cash and equivalents, Q1 FY2025, at 2025-03-31$271.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure307Cash and equivalents, Q2 FY2025, at 2025-06-30$306.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure351Cash and equivalents, Q3 FY2025, at 2025-09-30$350.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure335Cash and equivalents, FY2025, at 2025-12-31$334.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure298Cash and equivalents, Q1 FY2026, at 2026-03-31$298.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure478Cash and equivalents, Q2 FY2026, at 2026-06-30$477.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Current assets$m500Current assets, Q3 FY2023, at 2023-09-30$500.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure514Current assets, FY2023, at 2023-12-31$514.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-26, accession 0001821586-25-000006.Report this figure554Current assets, Q1 FY2024, at 2024-03-31$553.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure537Current assets, Q2 FY2024, at 2024-06-30$536.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure512Current assets, Q3 FY2024, at 2024-09-30$512.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure474Current assets, FY2024, at 2024-12-31$474.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure506Current assets, Q1 FY2025, at 2025-03-31$506.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure455Current assets, Q2 FY2025, at 2025-06-30$455.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure411Current assets, Q3 FY2025, at 2025-09-30$411.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure422Current assets, FY2025, at 2025-12-31$421.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure397Current assets, Q1 FY2026, at 2026-03-31$396.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure570Current assets, Q2 FY2026, at 2026-06-30$570.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Total assets$m500Total assets, Q3 FY2023, at 2023-09-30$500.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure527Total assets, FY2023, at 2023-12-31$526.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-26, accession 0001821586-25-000006.Report this figure564Total assets, Q1 FY2024, at 2024-03-31$564.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure545Total assets, Q2 FY2024, at 2024-06-30$544.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure518Total assets, Q3 FY2024, at 2024-09-30$518.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure478Total assets, FY2024, at 2024-12-31$477.9m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure511Total assets, Q1 FY2025, at 2025-03-31$511.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure460Total assets, Q2 FY2025, at 2025-06-30$460.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure414Total assets, Q3 FY2025, at 2025-09-30$414.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure424Total assets, FY2025, at 2025-12-31$424.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure400Total assets, Q1 FY2026, at 2026-03-31$400.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure574Total assets, Q2 FY2026, at 2026-06-30$573.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Current liabilities$m10.3Current liabilities, Q3 FY2023, at 2023-09-30$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure10.0Current liabilities, FY2023, at 2023-12-31$10.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-26, accession 0001821586-25-000006.Report this figure8.9Current liabilities, Q1 FY2024, at 2024-03-31$8.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure12.3Current liabilities, Q2 FY2024, at 2024-06-30$12.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure20.1Current liabilities, Q3 FY2024, at 2024-09-30$20.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure22.5Current liabilities, FY2024, at 2024-12-31$22.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure24.0Current liabilities, Q1 FY2025, at 2025-03-31$24.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure27.4Current liabilities, Q2 FY2025, at 2025-06-30$27.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure48.4Current liabilities, Q3 FY2025, at 2025-09-30$48.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure45.5Current liabilities, FY2025, at 2025-12-31$45.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure46.1Current liabilities, Q1 FY2026, at 2026-03-31$46.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure45.4Current liabilities, Q2 FY2026, at 2026-06-30$45.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Total liabilities$m10.6Total liabilities, Q3 FY2023, at 2023-09-30$10.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure13.0Total liabilities, FY2023, at 2023-12-31$13.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-26, accession 0001821586-25-000006.Report this figure11.7Total liabilities, Q1 FY2024, at 2024-03-31$11.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure14.8Total liabilities, Q2 FY2024, at 2024-06-30$14.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure22.7Total liabilities, Q3 FY2024, at 2024-09-30$22.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure24.5Total liabilities, FY2024, at 2024-12-31$24.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure98.7Total liabilities, Q1 FY2025, at 2025-03-31$98.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure102Total liabilities, Q2 FY2025, at 2025-06-30$102.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure123Total liabilities, Q3 FY2025, at 2025-09-30$123.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure120Total liabilities, FY2025, at 2025-12-31$120.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure146Total liabilities, Q1 FY2026, at 2026-03-31$146.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure146Total liabilities, Q2 FY2026, at 2026-06-30$145.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reported0.0Long-term debt, FY2024, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure73.0Long-term debt, Q1 FY2025, at 2025-03-31$73.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure73.4Long-term debt, Q2 FY2025, at 2025-06-30$73.4m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure73.7Long-term debt, Q3 FY2025, at 2025-09-30$73.7m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure74.1Long-term debt, FY2025, at 2025-12-31$74.1m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure99.0Long-term debt, Q1 FY2026, at 2026-03-31$99.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure99.5Long-term debt, Q2 FY2026, at 2026-06-30$99.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure
Short-term borrowings$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m425Shareholders' equity, Q3 FY2023, at 2023-09-30$424.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure496Shareholders' equity, FY2023, at 2023-12-31$495.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-02-26, accession 0001821586-25-000006.Report this figure543Shareholders' equity, Q1 FY2024, at 2024-03-31$542.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure521Shareholders' equity, Q2 FY2024, at 2024-06-30$520.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure488Shareholders' equity, Q3 FY2024, at 2024-09-30$488.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure447Shareholders' equity, FY2024, at 2024-12-31$446.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-25, accession 0001821586-26-000002.Report this figure408Shareholders' equity, Q1 FY2025, at 2025-03-31$407.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure354Shareholders' equity, Q2 FY2025, at 2025-06-30$353.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure289Shareholders' equity, Q3 FY2025, at 2025-09-30$288.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure304Shareholders' equity, FY2025, at 2025-12-31$304.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure254Shareholders' equity, Q1 FY2026, at 2026-03-31$254.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure428Shareholders' equity, Q2 FY2026, at 2026-06-30$428.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure

Cash flow

Operating cash flow−$55.6m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
Share repurchases$0, Q4 FY2024
MoonLake Immunotherapeutics, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(9.3)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$9.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0001821586-24-000029. Derived: 9-month figure less the 6-month figure.Report this figure(12.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$12.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(14.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$14.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure(27.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$27.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-05, accession 0001821586-25-000018. Derived: 6-month figure less the 3-month figure.Report this figure(25.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$25.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001821586-25-000022. Derived: 9-month figure less the 6-month figure.Report this figure(48.5)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$48.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(38.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$38.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(54.5)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$54.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001821586-26-000010. Derived: 6-month figure less the 3-month figure.Report this figure(44.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$44.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001821586-25-000022. Derived: 9-month figure less the 6-month figure.Report this figure(58.8)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$58.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure(66.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$66.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure(55.6)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$55.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001821586-26-000010. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0001821586-24-000029. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$284.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$212.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-05, accession 0001821586-25-000018. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$132.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001821586-25-000022. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2024, three months to 2024-12-31$176.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$35.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001821586-26-000010. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001821586-25-000022. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-25, accession 0001821586-26-000002. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001821586-26-000010. Derived: 6-month figure less the 3-month figure.Report this figure
Share repurchases$m0.0Share repurchases, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-11-07, accession 0001821586-24-000029. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2025-02-26, accession 0001821586-25-000006. Derived: 12-month figure less the 9-month figure.Report this figure0.0Share repurchases, Q1 FY2024, three months to 2024-03-31$50. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure0.0Share repurchases, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-08-07, accession 0001821586-24-000025. Derived: 6-month figure less the 3-month figure.Report this figure0.0Share repurchases, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-Q filed 2024-11-07, accession 0001821586-24-000029. Derived: 9-month figure less the 6-month figure.Report this figure0.0Share repurchases, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock. 10-K filed 2025-02-26, accession 0001821586-25-000006. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)73.92m, Q2 FY2026
MoonLake Immunotherapeutics, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares36.9Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3036,925,639 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001821586-23-000022.Report this figure39.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3139,061,977 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001821586-24-000020.Report this figure43.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3043,718,464 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-07, accession 0001821586-24-000025.Report this figure53.5Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3053,517,655 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001821586-24-000029.Report this figure62.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3162,637,212 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001821586-25-000011.Report this figure62.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3062,874,637 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-05, accession 0001821586-25-000018.Report this figure62.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3062,896,782 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure63.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3163,233,788 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure63.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3063,282,728 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure63.4Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3063,369,984 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001821586-25-000022.Report this figure71.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3171,273,650 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001821586-26-000007.Report this figure73.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3073,915,296 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure

Shares outstanding: 85.11mShares outstanding, period not labelled, at 2026-08-0185,106,685 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-10, accession 0001821586-26-000010.Report this figure at Aug 1, 2026, from the cover of the 10-Q filed Aug 10, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.